Bayani, Jane
Poncet, Coralie
Crozier, Cheryl http://orcid.org/0000-0002-0697-9913
Neven, Anouk http://orcid.org/0000-0003-2253-0427
Piper, Tammy
Cunningham, Carrie
Sobol, Monika
Aebi, Stefan http://orcid.org/0000-0002-3383-9449
Benstead, Kim
Bogler, Oliver
Dal Lago, Lissandra
Fraser, Judith
Hilbers, Florentine
Hedenfalk, Ingrid http://orcid.org/0000-0002-6840-3397
Korde, Larissa
Linderholm, Barbro
Martens, John http://orcid.org/0000-0002-3428-3366
Middleton, Lavinia
Murray, Melissa http://orcid.org/0000-0002-2935-6014
Kelly, Catherine http://orcid.org/0000-0001-8355-6714
Nilsson, Cecilia
Nowaczyk, Monika
Peeters, Stephanie
Peric, Aleksandra
Porter, Peggy
Schröder, Carolien
Rubio, Isabel T.
Ruddy, Kathryn J. http://orcid.org/0000-0001-6298-332X
van Asperen, Christi
Van Den Weyngaert, Danielle
van Deurzen, Carolien
van Leeuwen-Stok, Elise
Vermeij, Joanna http://orcid.org/0000-0003-0041-6957
Winer, Eric http://orcid.org/0000-0002-8819-1723
Giordano, Sharon H.
Cardoso, Fatima http://orcid.org/0000-0002-6692-2249
Bartlett, John M. S. http://orcid.org/0000-0002-0347-3888
Funding for this research was provided by:
Breast Cancer Research Foundation
Ontario Institute for Cancer Research
Article History
Received: 28 October 2020
Accepted: 24 June 2021
First Online: 26 July 2021
Competing interests
: The authors declare the following competing interests, no other competing interests have been declared: Dr. John Bartlett has received consultancies/honoraria from Insight Genetics, Inc., BioNTech AG, Biotheranostics, Inc., Pfizer, Rna Diagnostics Inc., oncoXchange/MedcomXchange Communications Inc, OncoCyte Corporation, NanoString Technologies, Inc., Oncology Education. Research funding from ThermoFisher Scientific, Genoptix, Agendia, NanoString Technologies, Inc., Stratifyer GmbH and Biotheranostics, Inc. Dr. Bartlett has received travel support from Biotheranostics, Inc., NanoString Technologies, Inc. and the Breast Cancer Society of Canada. Dr. Bartlett and Dr. Barbro Linderholm are members of advisory boards for Astra Zeneca, Pfizer, Eli Lilly, Novartis, Merck, and Daiichi Sankyo. Dr. Jane Bayani is a co-applicant on multiple patents including those for breast cancer prognostic signatures.